. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: J Subst Abuse Treat. 2020 Jun 15;116:108059. doi: 10.1016/j.jsat.2020.108059

Table 1.

Eligibility and assessment timetable

	BL	0^b	MIGT Sessions 1–6^a
	BL	0^b	Pre	During	Post
Enrollment
Informed Consent	X
Medical Screen	X
Allocation		X
Assessments
Sociodemographic	X
MINI 7.0.0	X
SCID-5, Suicide Assessment	X
ACE	X
ECR-S	X
STAI (full)	X
OTSE					X
Session Attendance				X
GQ					X
STAI-6			X		X
MCQ-Br			X		X
Urine Toxicology	X		X
TLFB			X
Physiology Recording				X

ACE = Adverse Childhood Experience Questionnaire, BL = Baseline, ECR-S = Experiences in Close Relationships – Short Form, GQ = Group Questionnaire, MCQ-Br = Methamphetamine Craving Questionnaire-Brief, MINI = Mini International Neuropsychiatric Interview, OTSE = Oxytocin Side Effect Checklist, SCID-5 = Structured Clinical Interview for DSM-5, STAI=State-Trait Anxiety Inventory, STAI-6 = State-Trait Anxiety Inventory Short Form, TLFB = Timeline Follow Back.

Intranasal study drug was administered 30 min prior to each MIGT session. “Pre”, “During", and “Post” refer to timing around MIGT session.

Enrollment.